14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
INCY vs MXCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INCY carries a Unified Composite Score of 54.6/100 (HOLD) at $114.62 (13.3x Forward P/E, 32.2% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).
Growth vs. Quality Trade-Off: INCY earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. MXCT 41.7/100 SELL) and 0.30β · 31% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: INCY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ INCY vs MXCT Key Questions & Quantitative Answers
As of Nov 20, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INCY carries a Unified Composite Score of 54.6/100 (HOLD) at $114.62 (13.3x Forward P/E, 32.2% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: INCY earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. MXCT 41.7/100 SELL) and 0.30β · 31% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: INCY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INCY leads the Growth & Scale pillar: INCY posts +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INCY cumulative revenue shifted +173.4% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, INCY deploys 23.8% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.
INCY screens cheaper on headline valuation multiples. INCY trades at 13.3x Forward P/E, 59.1x Trailing P/E, 10.82x PEG, and 3.4x EV/Revenue (11.3% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INCY (7.8% ROE) versus MXCT (-16.9% ROE) capital efficiency.
In options market volatility and institutional positioning, INCY carries 40.7% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.67x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 31% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.